Clinical trial NCT05630690: Evaluation of Safety and Efficacy of IPL Presets for Cutaneous Lesions
Official title: Evaluation of Safety and Efficacy of SMART Camera Treatment Presets for Cutaneous Lesions Using IPL in Skin Types I-V
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Vascular Lesion
Pigmented Lesions
Lead sponsor: Lumenis Be Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Emek Medical Center
First posted: 2022-11-30
Enrollment: 20
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Single-center, Prospective, Open-Label with Before-After Study Design. Each subject will receive up to three (3) consecutive treatments at 1-month interval. Treatment presets will be determined by the SMART Camera system and approved by the physician. Follow-up will take place at 1 month following the last treatment. Skin and lesion attributes will be examined by the SMART system and the physician on each visit and at follow-up.

Detailed description: Up to 20 healthy subjects, aged 21-80 years old with visible textural lesions including but not limited to Lentigines, Rosacea, and Age spots / Telangiectasia on the face or décolletage that wish to improve their skin appearance. Each patient should have at least 3 treatment areas (e.g. left cheek, right cheek, forehead, nose, chin, upper/lower décolletage) that contain at least one type of lesion.

Following the SMART Camera analysis, the system will suggest treatment presets. The physician will decide whether to use the treatment presets recommended by the AI system or modify them, based on the safety and efficacy of the suggested treatment presets.

Eligibility criteria: Inclusion Criteria:

1. Healthy Female/Male, age 21-80
2. Fitzpatrick skin type I-V
3. Presence of visible textural lesions including but not limited to:

   1. Lentigines
   2. Age spots / Telangiectasia (Photoaging treatment)
   3. Rosacea (Erythematotelangiectatic rosacea and papulopustular rosacea)
   4. Telangiectasia
4. Patients should have at least 3 treatment areas of the following: right cheek, left cheek, forehead, nose, chin, or upper/lower décolletage.
5. Able to read, understand and provide written Informed Consent.
6. Able and willing to comply with the treatment/follow-up schedule and requirements.
7. Willing to have digital photographs taken of all of the treatment areas before, during, and after the treatment.
8. Willing to refrain from using any prescription or over-the-counter topical creams used for the treatment of veins or pigmented lesions in the treatment area during the study period.
9. Willing to protect and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher in the treatment area, every day for the duration of the study.
10. Agree not to undergo any other procedure(s) in the same treatment areas during the study.
11. Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, or abstinence) at least 1 month prior to first treatment and throughout the course of the study.

Exclusion Criteria:

1. Previous treatments in the same area/s within twelve months prior to screening.
2. Fitzpatrick skin type VI.
3. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding.
4. Exposure to the sun or artificial tanning during 3-4 weeks prior to treatment. Any remaining suntan, sunburn, or artificial tanning products.
5. Active infections in the treatment area.
6. Dysplastic nevi.
7. Significant concurrent skin conditions or any inflammatory skin conditions.
8. Active cold sores, open lacerations, or abrasions in the treatment area.
9. Chronic or cutaneous viral, fungal or bacterial diseases.
10. Treatment should not be attempted on patients with a history or concurrent condition of skin cancer or pre-cancerous lesions in the treatment area
11. Tattoos in the treatment area.

Primary outcomes:
measure: To study the safety of the SMART IPL system platform for cutaneous lesions treatment in subjects with skin types I-V
timeFrame: End of treatments
Secondary outcomes:
measure: To study the efficacy of the SMART IPL system for cutaneous lesions treatment in subjects with skin types I-V
timeFrame: 1-month follow up
Other outcomes:
Locations:
city: Yoqne'am 'Illit
country: Israel
facility: Lumenis Be Ltd.
Study officials:
References: